ARS Pharmaceuticals, Inc. Common Stock (SPRY)

PHARMACEUTICAL PREPARATIONS

ARS Pharmaceuticals, Inc. Common Stock (SPRY) is listed on Nasdaq, where it has traded since November 9, 2022.

Listed On
Nasdaq
Listed Since
November 9, 2022
Employees
200
Market Cap
$406M

About ARS Pharmaceuticals, Inc. Common Stock

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 198 institutions reported holding SPRY, with 90.4 million shares worth $724.3 million in aggregate. The largest reported holder was RA Capital Management,, with 10.9 million shares worth $87.0 million. Of the 5 largest holders listed below, 2 added shares and 3 held their positions unchanged during the quarter.

InstitutionSharesValueQuarter change
RA Capital Management,10,860,977$87MUnchanged
Rubric Capital Management8,540,861$68MAdded 6.76%
Orbimed Advisors8,288,510$66MUnchanged
Deerfield Management Company,7,503,812$60MUnchanged
BlackRock5,311,319$43MAdded 5.97%

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions

What is SPRY?

ARS Pharmaceuticals, Inc. Common Stock (SPRY) is listed on Nasdaq, where it has traded since November 9, 2022.

Who are the largest institutional holders of SPRY?

In 13F filings for the quarter ended June 30, 2026, the largest reported holders of SPRY were RA Capital Management,, Rubric Capital Management and Orbimed Advisors.

How many institutions own SPRY?

198 institutions reported a position in SPRY for the quarter ended June 30, 2026, worth $724.3 million in total.

Did institutions buy or sell SPRY last quarter?

Of the 5 largest reported holders, 2 added shares and 3 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for SPRY.

Every reported institutional holder, plus insider and congressional trades in SPRY, on SentiSense.